BioSpace News Archive

PL-8177 Evaluated in Animal Models of Inflammatory Bowel Disease and Autoimmune Uveitis

Galli brings a patient perspective and extensive business experience to support LUNGevity’s strategic growth

-- June 30, 2018 PDUFA date for encorafenib and binimetinib NDAs in BRAF-mutant melanoma -- -- Encorafenib and binimetinib combination achieved a median overall survival (mOS) of 33.6 months in patients with BRAF-mutant melanoma in Phase 3 COLUMBUS trial --

Continued year-over-year revenue growth for XIAFLEX

Company’s innovative glycomics technology now addresses large population suffering from xerostomia

Program offers an intrinsically pleasurable approach to disease prevention and curbing the obesity crisis through visual weigh ins and cash incentives for weight loss

Design and results of clinical trials that led to FDA clearance of SeptiCyte™ LAB published in the American Journal of Respiratory and Clinical Care Medicine

Legal actions filed by patients with HIV from Los Angeles, San Diego & Marin Counties target Gilead over its promotion of HIV/AIDS medication that causes permanent damage to the kidneys and bones AND over Gilead’s suppression of a safer version of the drug with far less toxicity in order to maximize profits and extend the sales of the initial drug, tenofovir disoproxil fumarate (“TDF”).

Celonic AG has appointed Soenke Brunswieck as Vice President Cell & Gene Therapy to establish Celonic`s new portfolio of CDMO Services in Cell & Gene Therapy domain.

BrightFocus Foundation today announced that EyesOnALZ hit a major milestone by exceeding 10,000 citizen scientists joining to help speed up the time-consuming data analysis of stalled blood vessels in the brain. BrightFocus is the key funder of this effort.